Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Cetrelimab (JNJ 63723283，西利单抗) - 仅供科研 | PD-1单抗 | MCE
ESMO 2024: TAR-200 +/- Cetrelimab and Cetrelimab Alone in Patients with ...
ESMO 2021: Erdafitinib (ERDA) or ERDA Plus Cetrelimab (CET) for ...
Cetrelimab promoted T cell activation and reversed PD-1-mediated ...
Discovery and pharmacological characterization of cetrelimab (JNJ ...
In vitro, cetrelimab binds to PD-1 and blocks PD-1 ligand binding. a ...
ASCO GU 2023: SunRISe-4: TAR-200 plus Cetrelimab or Cetrelimab Alone as ...
Cetrelimab (JNJ 63723283) | PD-1 mAb | MedChemExpress
Cetrelimab | 西利单抗 | 抗 PD-1 | TargetMol
Combination Therapy in SunRISe-1: Lessons from Cetrelimab and TAR-200 ...
Cetrelimab – Application in Therapy and Current Clinical Research
EAU 2024: Trial in Progress: SunRISe-3: TAR-200 plus Cetrelimab or TAR ...
Cetrelimab showed antitumor efficacy in two in vivo models. a MC38 ...
SunRISe-4: primary and biomarker results of TAR-200 & cetrelimab in ...
Cetrelimab Recombinant Human Monoclonal Antibody, Invitrogen™ 100 μg ...
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as ...
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic ...
ESMO 2024: TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant ...
SunRISe-1: TAR-200, Cetrelimab for BCG-Unresponsive High-Risk NMIBC ...
TAR-200 + Cetrelimab Yields High pCR/RFS in MIBC: SunRISe-4 Data ...
Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in ...
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant ...
Neoadjuvant TAR-200 (intravesical gemcitabine) plus cetrelimab shows ...
Dr Necchi on TAR-200 & Cetrelimab in Bladder Cancer | Targeted Oncology ...
Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC ...
Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle ...
Amivantamab + Cetrelimab for Non-Small Cell Lung Cancer Clinical Trial ...
SunRISe-2 Study of TAR-200 Plus Cetrelimab in MIBC Discontinues ...
IBCN 2024: TAR-200 Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant ...
EAU 2025: Perioperative Outcomes of Neoadjuvant TAR-200 plus Cetrelimab ...
TAR-200 + Cetrelimab vs BCG for Bladder Cancer Clinical Trial 2024 | Power
Erdafitinib Plus Cetrelimab Elicits Durable Responses in Metastatic ...
ASCO GU 2026: Neoadjuvant Gemcitabine Intravesical System + Cetrelimab ...
AUA 2023: First Results from SunRISe-1 in Patients with BCG ...
ASCO 2025: C3NIRA: Randomized Phase II Study of Carboplatin-Cabazitaxel ...
强生FGFR激酶抑制剂Balversa联合PD-1抑制剂cetrelimab治疗尿路上皮癌：总缓解率达68%!-上市-医保-临床适应症-香港济民药业
First-in-human, open-label, phase 1/2 study of the monoclonal antibody ...
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Review of ...
Cetrelimab(Cetrelimab) - 药物靶点：PD-1_在研适应症：非肌层浸润性膀胱肿瘤，肌层浸润性膀胱癌，肌层浸润性膀胱尿路上 ...
IBCN 2024: TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or ...
(PDF) First-in-human, open-label, phase 1/2 study of the monoclonal ...
ESMO 2025: Neoadjuvant Gemcitabine Intravesical System (TAR-200 ...
(Cetrelimab)Biosimilar Reference Antibody
Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With ...
(PDF) Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in ...
ASCO GU 2026: Gemcitabine Intravesical System in Combination with ...
The High-Resolution Structure Reveals Remarkable Similarity in PD-1 ...
Neoadjuvant TAR-200/Cetrelimab Combo Generates Responses in Muscle ...
Frontiers | PD-1 N58-Glycosylation-Dependent Binding of Monoclonal ...
The Rise and Fall of Centralia | PA's Toxic Ghost Town - PA Bucket List
Thermo Fisher Scientific Unveils Revolutionary Mass Spectrometer for ...
TAR-200 Plus Cetrelimab: Advancing the Treatment Landscape of MIBC | GU ...
AUA 2024 Insights: "SunRISe-2 Study - Efficacy of TAR-200 in ...
(PDF) PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody ...
Immunotherapies used in combination regimens. The figure shows ...
Centralia Photos: Haunting Beauty Then & Now [Unbelievable ...
High-resolution crystal structure of the therapeutic antibody ...
尿路上皮癌(UC)新药！强生FGFR激酶抑制剂Balversa联合PD-1抑制剂cetrelimab：总缓解率达68%! - 专区 - 生物谷
Paragangliomas of the urinary bladder: Experience at the National ...
Centralia: An Abandoned Coal Mining Town in Pennsylvania
Biosimilar-Reference-Antibody-GS40128-ELISA-Mabnus.png)
